Evotec to Report Results for the First Nine Months of 2012 on 08 November 2012

Evotec to Report Results for the First Nine Months of 2012 on 08 November 2012

HAMBURG, Germany, Nov. 1, 2012 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT)
(TecDAX) will report its financial results for the first nine months of 2012
on Thursday, 08 November 2012.

The Company is going to hold a conference call to discuss the results as well
as to provide an update on its performance:

Conference call details:

Date: Thursday, 08 November 2012
Time:
09.30 a.m. CET
08.30 a.m. BST
03.30 a.m. US time (East Coast)

+49-(0)-69 58 999 0805 (Germany)
+44-207-153-2027 (UK)
+1-480-629-9726 (US)

Access Code: 4572580

A simultaneous slide presentation for participants dialling in via phone is
available at www.equitystory.com, password: evotec1112.

Webcast details

To join the audio webcast and to access the presentation slides you will find
a link on our home page www.evotec.com shortly before the event.

A replay of the conference call will be available for 24 hours and can be
accessed in Europe by dialling +49 69 58 99 90 568 (Germany) or +44 207 154
2833 (UK) and in the US by dialling +1 303 590 3030. The access code is
4572580#. The on-demand version of the webcast will be available on our
website:
http://www.evotec.com/article/en/Investors/Finance/Financial-Reports-2010-2012/188/6/26.

About Evotec AG

Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing the
highest quality stand-alone and integrated drug discovery solutions, covering
all activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and expertise
in key therapeutic areas including neuroscience, pain, metabolic diseases as
well as oncology and inflammation. Evotec has long-term discovery alliances
with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen
Pharmaceuticals, Inc., Medimmune/AstraZeneca, and Ono Pharmaceutical. In
addition, the Company has existing development partnerships and product
candidates both in clinical and preclinical development. These include
partnerships with Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the
field of diabetes, and with Roche in the field of Alzheimer's disease. For
additional information please go to www.evotec.com.

FORWARD LOOKING STATEMENTS — Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the
judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety
of risks and uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those contemplated in
these forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in events,
conditions or circumstances on which any such statement is based.

CONTACT: Dr Mario Polywka
         Chief Operating Officer
         +44.(0)1235.44 16 76
         +44.(0)1235.86 31 39 Fax
         mario.polywka@evotec.com
        
         Evotec AG
         Manfred Eigen Campus
         Essener Bogen 7
         22419 Hamburg (Deutschland)
 
Press spacebar to pause and continue. Press esc to stop.